Lupin Launches Authorized Generic Version of Ravicti in US
Global pharma major Lupin Limited has announced the launch of an authorized generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States.
Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for the chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets, specializing in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
No specific quote available in the text.
Author's summary: Lupin launches generic Ravicti in US.
More News
- Sonia Raman's Appointment Marks Milestone for Diversity in WNBA Coaching - sierraexpressmedia.com
- Flawless Bayern Munich post historic win at Borussia Mönchengladbach
- Why Trump Expects the Justice Department to Cut Him a Quarter-Billion-Dollar Check
- Assassin's Creed Shadows: Official Nintendo Switch 2 Release Date and Price Revealed
- Ole Miss visits Oklahoma in critical Week 9 SEC matchup - HottyToddy.com - Ole Miss Sports, Oxford Entertainment, Dining & More
- Kevin Porter Jr.'s absence already taking toll on Bucks
- Man United vs Brighton live: Full Premier League lineups
- Live updates: UFC 321 - Tom Aspinal v Ciryl Gane at Etihad Arena, Abu Dhabi
- Napoli v Inter Milan on TV – Watch Serie A football - TVWise.co.uk